Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate effects of smoking on the dopaminergic system by using PET tomography with new radioligand, \[11C\]-(+)-PHNO. Our primary hypothesis is that smoking a cigarette will produce dopamine release and this release can be measured using PET imaging and the \[11C\]-(+)-PHNO radiotracer. The secondary hypothesis is that this smoking induced dopamine release will be correlated with subjective craving and anxiety ratings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.

NCT00396669

Tobacco Use Disorder

UNKNOWN NA

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm

NCT01699607

Nicotine Dependence Healthy

COMPLETED NA

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

NCT05011760

Cocaine Use Disorder

RECRUITING EARLY_PHASE1

Imaging the Neurochemistry of Drug Addiction With PET

NCT02817698

Smoking Cannabis

COMPLETED EARLY_PHASE1

PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration

NCT00846339

Smoking

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a within-subjects study in healthy male and female smokers. There will be one within factor condition: Smoking and Non Smoking. Therefore, there will be a repeated measure of PET scans using \[11C\]-(+)-PHNO under two different conditions. Ten subjects (n=5 male and n=5 female) included in the study will come on two different days and will have a Smoking or Non smoking session performed just before the PET study. Subjective assessments will be conducted at each experimental condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy smokers

Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult males or females
* Regular smoking of at least 10 cigarettes, excluding ultra-low nicotine cigarettes, per day for at least two years
* Score on the Fagerstrom Test for Nicotine Dependence of 4 or more
* No intention to quit or reduce tobacco use, and no treatment for tobacco dependence currently
* No history of abuse of or dependence on any other drug, defined by DSM-IV criteria

Exclusion Criteria

* Pregnancy
* Presence of metal objects in the body or implanted electronic devices, that preclude safe MR scanning
* Claustrophobia
* Cardiovascular or cerebrovascular diseases
* Major psychiatric disorders including mood, anxiety or psychotic disorders
* History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor
* Gross structural brain abnormalities as revealed by T1 weighted images
* Current use or use during the previous month of medication that may affect the CNS (e.g. neuroleptics, bupropion)
* Learning disability, amnesia or other conditions that impede memory and attention

Minimum Eligible Age

21 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No